Table 1

Demographic and baseline characteristics, by dose

DemographicValuec
5 μg (n = 6)25 μg (n = 6)50 μga (n = 12)100 μgb (n = 12)Total (n = 36)
Gender, no. (%)
    Male3 (50)1 (16.7)7 (58.3)8 (66.7)19 (52.8)
    Female3 (50)5 (83.3)5 (41.7)4 (33.3)17 (47.2)
Ethnicity, no. (%)
    Non-Hispanic or Non-Latino6 (100)6 (100)11 (91.7)12 (100)35 (97.2)
    Hispanic or Latino001 (8.3)01 (2.8)
Race, no. (%)
    Black/African American2 (33.3)5 (83.3)8 (66.7)7 (58.3)22 (61.1)
    White4 (66.7)1 (16.7)3 (25)4 (33.3)12 (33.3)
    Multiracial001 (8.3)01 (2.8)
    Other/unknown0001 (8.3)1 (2.8)
Age (yrs)
    Mean (SD)29.0 (8.7)28.8 (8.8)33.1 (7.3)32.3 (7.8)31.4 (7.8)
    Median29.027.535.030.530.5
    Min, max19, 4320, 4119, 4321, 4419, 44
Age group, no. (%)
    18–30 yrs4 (66.7)4 (66.7)4 (33.3)6 (50)18 (50)
    >30 yrs2 (33.3)2 (33.3)8 (66.7)6 (50)18 (50)
  • a Six subjects were dosed with 50 μg in cohort 3 and another six were dosed in cohort 5.

  • b Six subjects were dosed with 100 μg in cohort 4 and another six were dosed in cohort 5.

  • c The denominator for percentages is the no. of subjects in the population for each dose.